

## Ampyra (dalfampridine) Prior Authorization of Benefits Form

## CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004 or Provider Help Desk at 1-800-454-3730.

| 1. Patient information   |             | 2. Physician information |                         |  |
|--|-------------|--------------------------|-------------------------|--|
| Patient name:  |             | Prescribing physician:   |                         |  |
| Patient ID #:  |             |                          |                         |  |
| Patient DOB:   |             | Physician phone #:       |                         |  |
| <br>Date of Rx:  |             | Physician fax #:         |                         |  |
| Patient phone #:   |             |                          |                         |  |
| Patient email address:   |             | Physician DEA:           |                         |  |
|  |             | Physician NPI #:         |                         |  |
|  |             | Physician email address: |                         |  |
| 3. Medication  | 4. Strength | 5. Directions            | 6. Quantity per 30 days |  |
|  |             |                          | Specify:                |  |
|  |             |                          |                         |  |
| 7. Diagnosis:  |             |                          |                         |  |
| 8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)   |             |                          |                         |  |
| Prior authorization is required for dalfampridine (Ampyra <sup>™</sup> ). Payment will be considered under the following conditions: 1) Patients must be diagnosed with a gait disorder associated with multiple sclerosis (MS), 2) Initial authorizations will be approved for 12 weeks with a baseline timed 25-foot walk (T25FW) assessment, 3) Additional prior authorizations will be considered at six month intervals after assessing the benefit to the patient as measured by a 20 percent improvement in the T25FW from baseline. Renewal will not be approved if the 20 percent improvement is not maintained. Prior authorizations will not be considered for patients with a seizure diagnosis or in patients with moderate or severe renal impairment. |             |                          |                         |  |
| Preferred Dalfampridine ER Result of the baseline T25FW assessment:  |             | onpreferred<br>] Ampyra  |                         |  |
| Date of the baseline T25FW assessment :  |             |                          |                         |  |

| Date of subsequent T25FW assessment<br>Percent improvement from baseline assessment<br>Patient has a seizure diagnosis:  |      |  |  |  |
|--|------|--|--|--|
| Attach lab results and other documentation as necessary.   |      |  |  |  |
| 9. Physician signature   |      |  |  |  |
|  |      |  |  |  |
| Prescriber or authorized signature   | Date |  |  |  |
| Prior authorization of benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations and exclusions. The submitting provider certifies that the information provided is true, accurate and complete and the requested services are medically indicated and necessary to the health of the patient. |      |  |  |  |

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.